Scenic Biotech B.V., founded in 2017 and based in Amsterdam, specializes in developing genomics and immunotherapy technologies aimed at addressing cancer and rare genetic diseases at their genetic roots. The company focuses on identifying disease-suppressing genes that serve as "off-switches" for GPCR signaling, enabling innovative therapeutic interventions. Scenic Biotech's approach involves unlocking genetic modifiers that can suppress or block the effects of disease-causing mutated genes. This technology allows for the rapid identification and validation of novel drug targets, facilitating the development of disease-modifying therapeutics that aim to improve the lives of patients suffering from severe conditions.
Memo Therapeutics AG, based in Basel, Switzerland, specializes in antibody discovery and immune repertoire analysis through its innovative MemoMAB platform. This technology enables the creation of a recombinant in vitro copy of an individual’s B cell and antibody repertoire, resulting in unique and extensive libraries that reflect a person's immune response. These libraries are anticipated to contain a significant number of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics employs its MemoMAB platform in proprietary antibody lead discovery programs and offers it for collaboration with other entities, enhancing the potential for novel therapeutic developments.
Rejuvenate Biomed is a biomedical company researching the biology of aging & applying this knowledge to identify safe and well tolerated drugs to maintain and restore our natural cell resilience capacity improving the respons to age-related diseases.
Caresyntax Inc. develops a technology platform specializing in surgical analytics to enhance safety and efficiency in hospitals and ambulatory surgical centers. The company offers solutions designed to identify and manage risks, automate workflows, and reduce variability in surgical procedures. Its flagship products include qvident, a performance management software that enables surgical teams to create and share surgical content, and PRIME365, an integration platform that consolidates key surgical data from various sources such as video, audio, patient vitals, and procedural timestamps. Caresyntax's offerings support a range of surgical procedures, from minimally invasive to robotic surgeries, and can be deployed as HIPAA-compliant software through on-premise, cloud-based, or hybrid installations. Established in 1991, Caresyntax is headquartered in Boston, Massachusetts.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address significant unmet medical needs, particularly in autoimmune diseases, allergies, and anti-drug antibodies. The company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. This approach targets liver sinusoidal endothelial cells to promote tolerance against blood-borne antigens. Topas is advancing several clinical-stage programs, with its lead candidate, TPM203, currently in clinical testing for pemphigus vulgaris, an orphan disease. Other therapeutic programs under development include treatments for celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research collaborations with Eli Lilly and Company and Boehringer Ingelheim to enhance its capabilities in antigen-specific tolerance induction and anti-drug antibodies, respectively. Topas Therapeutics was incorporated in 2013 and is dedicated to finding innovative solutions for chronic immunological conditions.
Caresyntax Inc. develops a technology platform specializing in surgical analytics to enhance safety and efficiency in hospitals and ambulatory surgical centers. The company offers solutions designed to identify and manage risks, automate workflows, and reduce variability in surgical procedures. Its flagship products include qvident, a performance management software that enables surgical teams to create and share surgical content, and PRIME365, an integration platform that consolidates key surgical data from various sources such as video, audio, patient vitals, and procedural timestamps. Caresyntax's offerings support a range of surgical procedures, from minimally invasive to robotic surgeries, and can be deployed as HIPAA-compliant software through on-premise, cloud-based, or hybrid installations. Established in 1991, Caresyntax is headquartered in Boston, Massachusetts.
Rejuvenate Biomed is a biomedical company researching the biology of aging & applying this knowledge to identify safe and well tolerated drugs to maintain and restore our natural cell resilience capacity improving the respons to age-related diseases.
SWORD Health develops innovative technology solutions for the treatment of musculoskeletal disorders, allowing patients to engage in therapy from home. Founded in 2012 and headquartered in Porto, Portugal, the company combines licensed physical therapists with digital tools to provide effective care for chronic and post-surgical pain. Since its launch in 2015, SWORD Health has collaborated with insurers, health systems, and employers across Europe, Australia, and the United States, enabling thousands to access preventive and therapeutic musculoskeletal care. The company’s platform offers interactive rehabilitation exercises supervised by remote physiotherapists, facilitating independent use and reducing overall treatment costs. Through its mission to alleviate pain for two billion individuals, SWORD Health aims to transform the landscape of physical rehabilitation without relying on imaging, surgeries, or opioids. The company maintains offices in major cities, including New York City, Chicago, Salt Lake City, and Sydney.
CatalYm GmbH, founded in 2016 and based in Munich, Germany, specializes in the development of immuno-oncology therapeutics. The company focuses on creating antibodies that target a placental factor known to be overexpressed in various tumor types. Through its innovative approach, CatalYm aims to enhance cancer treatment options and improve patient outcomes in the field of oncology.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address significant unmet medical needs, particularly in autoimmune diseases, allergies, and anti-drug antibodies. The company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. This approach targets liver sinusoidal endothelial cells to promote tolerance against blood-borne antigens. Topas is advancing several clinical-stage programs, with its lead candidate, TPM203, currently in clinical testing for pemphigus vulgaris, an orphan disease. Other therapeutic programs under development include treatments for celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research collaborations with Eli Lilly and Company and Boehringer Ingelheim to enhance its capabilities in antigen-specific tolerance induction and anti-drug antibodies, respectively. Topas Therapeutics was incorporated in 2013 and is dedicated to finding innovative solutions for chronic immunological conditions.
SWORD Health develops innovative technology solutions for the treatment of musculoskeletal disorders, allowing patients to engage in therapy from home. Founded in 2012 and headquartered in Porto, Portugal, the company combines licensed physical therapists with digital tools to provide effective care for chronic and post-surgical pain. Since its launch in 2015, SWORD Health has collaborated with insurers, health systems, and employers across Europe, Australia, and the United States, enabling thousands to access preventive and therapeutic musculoskeletal care. The company’s platform offers interactive rehabilitation exercises supervised by remote physiotherapists, facilitating independent use and reducing overall treatment costs. Through its mission to alleviate pain for two billion individuals, SWORD Health aims to transform the landscape of physical rehabilitation without relying on imaging, surgeries, or opioids. The company maintains offices in major cities, including New York City, Chicago, Salt Lake City, and Sydney.
OncoDNA SA is a Belgium-based company specializing in precision medicine for cancer treatment and genetic diseases. Founded in 2012, it leverages over 60 years of expertise in medical diagnostics, particularly in DNA sequencing and oncology analyses. The company offers a range of solutions, including OncoDEEP, a comprehensive theranostics tool for solid tumors that integrates DNA, RNA, and protein analysis to assist oncologists in making informed treatment decisions. Additionally, OncoDEEP&TRACE allows for the profiling of both solid and liquid biopsies, while OncoTRACE provides a personalized, non-invasive blood test for monitoring tumor progression and treatment efficacy. OncoSHARE facilitates collaboration among patients, oncologists, and the oncology community by streamlining sample management and data sharing. OncoDNA distributes its products both locally in Belgium and globally, supporting clinical guidance and research in oncology and genetic disorders.
Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of custom orthopedic aids, including orthoses and prostheses. The company empowers orthopedic and prosthetic (O&P) professionals through its Mecuris Solution Platform, which integrates digital technology and 3D printing. This platform allows for the co-creation of individualized O&P products by utilizing patient data and scans to semi-automatically generate custom 3D designs. These designs can be printed locally, ensuring a tailored fit and reducing production times by up to 75%. Mecuris aims to enhance the lives of wearers by providing quick, personalized solutions that meet their specific needs.
Tonic App S.A. is a digital health company that has developed a mobile application aimed at enhancing communication and collaboration among medical professionals. The application serves as a comprehensive platform for doctors to message, share, and archive patient cases, request expert advice, and network with peers. It also enables hospitals, pharmaceutical companies, and medical associations to connect with healthcare professionals and disseminate relevant medical content. Key features of the app include tools for coordinating urgent procedures, discussing clinical cases, sharing medical images, and accessing a range of healthcare resources, such as clinical calculators and drug conversion tables. Founded in 2016 and headquartered in Porto, Portugal, Tonic App strives to improve the efficiency of medical practice and patient outcomes through its integrated approach to health content aggregation and team collaboration. The application is available on Google Play.
Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, founded in 2013. The company specializes in the tissue-specific regulation of sex hormone effects and is focused on developing innovative treatments for urological and endocrinological diseases. Its lead product, Fispemifene, is a selective estrogen receptor modulator designed to address symptoms related to low testosterone in men. Additionally, Forendo is working on a 17HSD1-inhibitor aimed at treating endometriosis. By targeting specific hormone mechanisms, Forendo Pharma seeks to enhance treatment options for both male and female health conditions, addressing unmet medical needs in these areas.
DEARhealth, Inc. is a health technology company based in Beverly Hills, California, that specializes in developing a software-as-a-service (SaaS) healthcare management platform tailored for medical providers and health insurers. Founded in 2013, the company focuses on value-based healthcare solutions aimed at enhancing the health outcomes and experiences of chronically ill patients while simultaneously reducing associated costs. Utilizing advanced data analytics, DEARhealth's platform facilitates coordinated care pathways, streamlines provider workflows, and supports organizational decision-making. The technology is specifically designed for the management of complex and costly diseases, enabling healthcare professionals to optimize care and improve measurable patient outcomes.
Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of custom orthopedic aids, including orthoses and prostheses. The company empowers orthopedic and prosthetic (O&P) professionals through its Mecuris Solution Platform, which integrates digital technology and 3D printing. This platform allows for the co-creation of individualized O&P products by utilizing patient data and scans to semi-automatically generate custom 3D designs. These designs can be printed locally, ensuring a tailored fit and reducing production times by up to 75%. Mecuris aims to enhance the lives of wearers by providing quick, personalized solutions that meet their specific needs.
OMEICOS Therapeutics GmbH is a biotechnology company focused on developing innovative therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases. Established in 2013 and headquartered in Berlin, Germany, the company is pioneering a first-in-class small molecule that leverages a unique mode of action based on natural metabolites of omega-3 fatty acids. These metabolites exhibit strong anti-arrhythmic properties by activating an endogenous cardio-protective signaling pathway, which not only stabilizes heart rhythm but also aims to provide curative effects by preventing electrical and structural remodeling of the heart. OMEICOS' approach is designed to offer safe and effective treatment options for patients with cardiovascular conditions, while also addressing inflammatory diseases and other indications.
Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, founded in 2013. The company specializes in the tissue-specific regulation of sex hormone effects and is focused on developing innovative treatments for urological and endocrinological diseases. Its lead product, Fispemifene, is a selective estrogen receptor modulator designed to address symptoms related to low testosterone in men. Additionally, Forendo is working on a 17HSD1-inhibitor aimed at treating endometriosis. By targeting specific hormone mechanisms, Forendo Pharma seeks to enhance treatment options for both male and female health conditions, addressing unmet medical needs in these areas.
SWORD Health develops innovative technology solutions for the treatment of musculoskeletal disorders, allowing patients to engage in therapy from home. Founded in 2012 and headquartered in Porto, Portugal, the company combines licensed physical therapists with digital tools to provide effective care for chronic and post-surgical pain. Since its launch in 2015, SWORD Health has collaborated with insurers, health systems, and employers across Europe, Australia, and the United States, enabling thousands to access preventive and therapeutic musculoskeletal care. The company’s platform offers interactive rehabilitation exercises supervised by remote physiotherapists, facilitating independent use and reducing overall treatment costs. Through its mission to alleviate pain for two billion individuals, SWORD Health aims to transform the landscape of physical rehabilitation without relying on imaging, surgeries, or opioids. The company maintains offices in major cities, including New York City, Chicago, Salt Lake City, and Sydney.
Ncardia BV is a biotechnology company based in Leiden, the Netherlands, that specializes in developing and manufacturing human induced pluripotent stem cell-based solutions for drug discovery and cell therapy. Established in 2017, the company focuses on expediting the drug discovery and development process by utilizing high-quality iPSC technology. Ncardia's offerings include disease modeling, assay development, large-scale iPSC manufacturing, and iPSC-based screening. These capabilities enable researchers to conduct predictive human cellular assays for safety and efficacy testing of drug candidates, specifically enhancing cardiovascular and neural drug screening. Through its innovative approaches, Ncardia aims to provide valuable insights into human disease biology, thereby accelerating the overall drug discovery process.
OMEICOS Therapeutics GmbH is a biotechnology company focused on developing innovative therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases. Established in 2013 and headquartered in Berlin, Germany, the company is pioneering a first-in-class small molecule that leverages a unique mode of action based on natural metabolites of omega-3 fatty acids. These metabolites exhibit strong anti-arrhythmic properties by activating an endogenous cardio-protective signaling pathway, which not only stabilizes heart rhythm but also aims to provide curative effects by preventing electrical and structural remodeling of the heart. OMEICOS' approach is designed to offer safe and effective treatment options for patients with cardiovascular conditions, while also addressing inflammatory diseases and other indications.
Exact Imaging develops high-resolution micro-ultrasound systems for enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Its micro-ultrasound system enables visualization and targeting of suspicious regions, in addition to performing systematic TRUS biopsies for prostate cancer imaging and the surrounding anatomy. The company also offers FusionVu micro-ultrasound/MRI fusion application to complement its ExactVu micro-ultrasound system for prostate imaging and biopsy. Exact Imaging was formerly known as Imagistx, Inc. and changed its name to Exact Imaging in March 2015. The company was founded in 2003 and is based in Markham, Canada.
Promethera Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver diseases. Founded in 2009 and based in Mont-Saint-Guibert, Belgium, with an office in Tokyo, Japan, the company specializes in cell therapy products, notably HepaStem and H2Stem, which utilize allogeneic progenitor cells derived from healthy human adult livers. Promethera is actively working on treatments for a range of conditions, including acute-on-chronic liver failure, hemophilia, liver fibrosis, non-alcoholic steatohepatitis, liver-based metabolic diseases, and urea cycle disorders. The company also engages in strategic alliances to further its research and development efforts, enhancing its capacity to discover and commercialize effective cell therapies for liver-related ailments.
Ogeda SA, a clinical-stage drug discovery company, invents and develops small molecule drugs targeting G-Protein Coupled Receptors. It offers fezolinetant (ESN364), a Phase II clinical development product for the treatment of women’s health disorders; NK3 antagonists for the treatment of hormone-dependent pathologies in women's health; and products for endocrine, CNS/inflammatory disorders. Ogeda SA was formerly known as Euroscreen SA and changed its name to Ogeda SA in October 2016. The company was founded in 1994 and is based in Gosselies, Belgium. It has a meeting facility in Brussels, Belgium; and an additional office in Paris, France. Ogeda SA operates as a subsidiary of Astellas Pharma Inc.
Apitope International NV is a biotechnology company based in Diepenbeek, Belgium, with a presence in the United Kingdom. Founded in 2002, it specializes in the discovery and development of therapeutic vaccines and peptides aimed at treating allergy and autoimmune diseases, including multiple sclerosis, Graves’ disease, and uveitis. Apitope's innovative approach focuses on developing disease-modifying therapies that selectively address the underlying causes of these conditions. Notable products in its pipeline include ATX-MS-1467 for multiple sclerosis, as well as candidates for Factor VIII intolerance and Graves’ disease. The company's proprietary platform technology supports its ongoing development efforts, with its first product candidate already licensed to a major pharmaceutical firm. Through its work, Apitope aims to enhance the quality of life for patients suffering from these challenging diseases.
OMEICOS Therapeutics GmbH is a biotechnology company focused on developing innovative therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases. Established in 2013 and headquartered in Berlin, Germany, the company is pioneering a first-in-class small molecule that leverages a unique mode of action based on natural metabolites of omega-3 fatty acids. These metabolites exhibit strong anti-arrhythmic properties by activating an endogenous cardio-protective signaling pathway, which not only stabilizes heart rhythm but also aims to provide curative effects by preventing electrical and structural remodeling of the heart. OMEICOS' approach is designed to offer safe and effective treatment options for patients with cardiovascular conditions, while also addressing inflammatory diseases and other indications.
Genkyotex SA is a biopharmaceutical company based in Labège, France, focusing on the development of innovative oral small molecule therapies that selectively inhibit NOX enzymes implicated in various disease processes. The company's lead candidate, GKT831, is a NOX1 and NOX4 inhibitor undergoing Phase II clinical trials for primary biliary cholangitis, a fibrotic orphan disease, and type 1 diabetes with kidney complications. In addition, Genkyotex is advancing GKT771, a preclinical NOX1 inhibitor aimed at addressing pain processing and inflammation. The company also holds a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for developing multivalent combination vaccines against infectious diseases. Genkyotex's technology is designed to treat oxygen-radical mediated acute and chronic diseases, offering improved specificity and safety compared to existing antioxidant therapies, and targets cardiovascular, metabolic, and neurodegenerative conditions. Founded in 2006, Genkyotex is committed to enhancing patient outcomes through its research and development initiatives.
Humedics GmbH, founded in 2009 and based in Berlin, Germany, specializes in the development of a breath analysis device designed to assess liver function in patients suffering from liver failure. The company's key product, the LiMAx test, is a diagnostic system that includes a medical device, breath masks, and a diagnostic drug, enabling clinicians to quantitatively evaluate individual liver function. This technology supports various applications, such as assessing liver function before and after transplantation, planning liver surgeries, and evaluating conditions like liver cirrhosis. By providing rapid and precise measurements at the bedside, LiMAx facilitates informed decision-making for tailored medical treatments, thereby enhancing patient outcomes. The company has successfully used its technology with thousands of patients and is focused on expanding its global operations.
Ncardia BV is a biotechnology company based in Leiden, the Netherlands, that specializes in developing and manufacturing human induced pluripotent stem cell-based solutions for drug discovery and cell therapy. Established in 2017, the company focuses on expediting the drug discovery and development process by utilizing high-quality iPSC technology. Ncardia's offerings include disease modeling, assay development, large-scale iPSC manufacturing, and iPSC-based screening. These capabilities enable researchers to conduct predictive human cellular assays for safety and efficacy testing of drug candidates, specifically enhancing cardiovascular and neural drug screening. Through its innovative approaches, Ncardia aims to provide valuable insights into human disease biology, thereby accelerating the overall drug discovery process.
Trod Medical S.A. is a medical equipment and surgical device manufacturer founded in 2006, with headquarters in Leuven, Belgium, and a presence in the Tampa Bay area, USA. The company specializes in developing innovative ablation technologies, particularly focusing on radiofrequency (RF) ablation devices. Trod Medical's flagship product, the EncageTM, is a disruptive percutaneous RF device that enables precise tissue ablation, significantly reducing collateral damage—a critical concern in treatments for conditions such as prostate cancer. With prostate cancer being one of the most prevalent cancers, affecting approximately 240,000 new patients annually in the United States, Trod Medical's technology addresses the limitations of conventional treatments that often lead to severe side effects, including erectile dysfunction and urinary incontinence. The company aims to enhance patient outcomes through its advanced medical devices designed for the focal ablation of soft tissues.
Complix NV is a biopharmaceutical company based in Diepenbeek, Belgium, with research facilities in Zwijnaarde, Belgium, and an office in Esch-sur-Alzette, Luxembourg. Founded in 2008, the company specializes in the discovery and development of Alphabodies, a novel class of protein therapeutics designed to target difficult disease sites, particularly in oncology and autoimmune diseases. These Alphabodies demonstrate high affinity for a variety of disease targets and possess unique stability and versatility, enabling non-injectable delivery methods. Complix aims to address challenging intracellular targets, thereby offering patients alternatives to traditional antibodies and small molecules, with the intent of improving treatment outcomes for complex conditions such as cancer, autoimmune disorders, and viral diseases.
FF Pharmaceuticals BV is a biopharmaceutical company based in Utrecht, the Netherlands, specializing in the development of disease-modifying therapeutics for inflammatory and autoimmune diseases. The company focuses on an anti-CD40 monoclonal antibody therapy designed to treat chronic inflammatory conditions such as primary biliary cirrhosis and Crohn's disease. This therapy acts as a negative allosteric modulator of the CD40 pathway, functioning as a reversible switch for B cell activation and inhibiting immune responses. By targeting the CD40 pathway, FF Pharmaceuticals aims to address the underlying immune dysregulation associated with these diseases, offering potential new treatment options for patients.
Private Equity Round in 2012
Ogeda SA, a clinical-stage drug discovery company, invents and develops small molecule drugs targeting G-Protein Coupled Receptors. It offers fezolinetant (ESN364), a Phase II clinical development product for the treatment of women’s health disorders; NK3 antagonists for the treatment of hormone-dependent pathologies in women's health; and products for endocrine, CNS/inflammatory disorders. Ogeda SA was formerly known as Euroscreen SA and changed its name to Ogeda SA in October 2016. The company was founded in 1994 and is based in Gosselies, Belgium. It has a meeting facility in Brussels, Belgium; and an additional office in Paris, France. Ogeda SA operates as a subsidiary of Astellas Pharma Inc.
Genkyotex SA is a biopharmaceutical company based in Labège, France, focusing on the development of innovative oral small molecule therapies that selectively inhibit NOX enzymes implicated in various disease processes. The company's lead candidate, GKT831, is a NOX1 and NOX4 inhibitor undergoing Phase II clinical trials for primary biliary cholangitis, a fibrotic orphan disease, and type 1 diabetes with kidney complications. In addition, Genkyotex is advancing GKT771, a preclinical NOX1 inhibitor aimed at addressing pain processing and inflammation. The company also holds a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for developing multivalent combination vaccines against infectious diseases. Genkyotex's technology is designed to treat oxygen-radical mediated acute and chronic diseases, offering improved specificity and safety compared to existing antioxidant therapies, and targets cardiovascular, metabolic, and neurodegenerative conditions. Founded in 2006, Genkyotex is committed to enhancing patient outcomes through its research and development initiatives.
Trinean is a Belgium based technology provider, bringing micro-volume molecular spectroscopy to the next level by combining best in class analytical software with a highly standardized read-out platform. Founded in 2006 as a spin-out of the Ghent University, Belgium and Imec Leuven, Belgium, the company commercializes UV/VIS spectrometers for biomolecule quantification. The DropSense™16 and DropSense™96, analyzing up to 16 and 96 samples resp., use microfluidic chips for standardized sample analysis (DropPlates™ and Slides). The Trinean platform is complemented with a software toolbox for improved data interpretation and lab-automation.
Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique ‘Localized Drug Action' platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.
ProFibrix B.V. is a biotech company founded in 2004 that specializes in the development and marketing of products for the hemostasis and regenerative medicine markets. The company’s primary product, Fibrocaps, is a dry powder topical hemostat and tissue sealant made from a combination of fibrinogen and thrombin, aimed at stopping acute and severe bleeding during surgical procedures or following traumatic injuries. ProFibrix also provides a sterilized single-use delivery device designed to apply Fibrocaps directly to the target tissue, minimizing disruption to the wound. The company’s products leverage human fibrinogen, a natural blood protein, to enhance hemostasis, blood clotting, and tissue repair.
Genkyotex SA is a biopharmaceutical company based in Labège, France, focusing on the development of innovative oral small molecule therapies that selectively inhibit NOX enzymes implicated in various disease processes. The company's lead candidate, GKT831, is a NOX1 and NOX4 inhibitor undergoing Phase II clinical trials for primary biliary cholangitis, a fibrotic orphan disease, and type 1 diabetes with kidney complications. In addition, Genkyotex is advancing GKT771, a preclinical NOX1 inhibitor aimed at addressing pain processing and inflammation. The company also holds a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for developing multivalent combination vaccines against infectious diseases. Genkyotex's technology is designed to treat oxygen-radical mediated acute and chronic diseases, offering improved specificity and safety compared to existing antioxidant therapies, and targets cardiovascular, metabolic, and neurodegenerative conditions. Founded in 2006, Genkyotex is committed to enhancing patient outcomes through its research and development initiatives.
Activaero GmbH is a drug delivery company focused on the research, development, manufacture, and marketing of controlled breathing technologies for inhaled therapeutic agents. Based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero offers a range of innovative products, including AKITA, a controlled breathing device equipped with smart card technology, and Watchhaler, designed specifically for children requiring inhaled medication. The company's technologies aim to ensure efficient and safe drug deposition in the lungs, addressing severe respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis. Activaero also provides AKITA² for clinical trial settings and LimiX, a flow limitation valve that regulates flow rates. Additionally, the company offers measurement and diagnostic technologies for laboratory use and contract development services for clinical trials. Its products are marketed through a network of distributors. Founded in 2004, Activaero is dedicated to improving therapy outcomes for patients with lung diseases.
Complix NV is a biopharmaceutical company based in Diepenbeek, Belgium, with research facilities in Zwijnaarde, Belgium, and an office in Esch-sur-Alzette, Luxembourg. Founded in 2008, the company specializes in the discovery and development of Alphabodies, a novel class of protein therapeutics designed to target difficult disease sites, particularly in oncology and autoimmune diseases. These Alphabodies demonstrate high affinity for a variety of disease targets and possess unique stability and versatility, enabling non-injectable delivery methods. Complix aims to address challenging intracellular targets, thereby offering patients alternatives to traditional antibodies and small molecules, with the intent of improving treatment outcomes for complex conditions such as cancer, autoimmune disorders, and viral diseases.
Promethera Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver diseases. Founded in 2009 and based in Mont-Saint-Guibert, Belgium, with an office in Tokyo, Japan, the company specializes in cell therapy products, notably HepaStem and H2Stem, which utilize allogeneic progenitor cells derived from healthy human adult livers. Promethera is actively working on treatments for a range of conditions, including acute-on-chronic liver failure, hemophilia, liver fibrosis, non-alcoholic steatohepatitis, liver-based metabolic diseases, and urea cycle disorders. The company also engages in strategic alliances to further its research and development efforts, enhancing its capacity to discover and commercialize effective cell therapies for liver-related ailments.
Activaero GmbH is a drug delivery company focused on the research, development, manufacture, and marketing of controlled breathing technologies for inhaled therapeutic agents. Based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero offers a range of innovative products, including AKITA, a controlled breathing device equipped with smart card technology, and Watchhaler, designed specifically for children requiring inhaled medication. The company's technologies aim to ensure efficient and safe drug deposition in the lungs, addressing severe respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis. Activaero also provides AKITA² for clinical trial settings and LimiX, a flow limitation valve that regulates flow rates. Additionally, the company offers measurement and diagnostic technologies for laboratory use and contract development services for clinical trials. Its products are marketed through a network of distributors. Founded in 2004, Activaero is dedicated to improving therapy outcomes for patients with lung diseases.
Apitope International NV is a biotechnology company based in Diepenbeek, Belgium, with a presence in the United Kingdom. Founded in 2002, it specializes in the discovery and development of therapeutic vaccines and peptides aimed at treating allergy and autoimmune diseases, including multiple sclerosis, Graves’ disease, and uveitis. Apitope's innovative approach focuses on developing disease-modifying therapies that selectively address the underlying causes of these conditions. Notable products in its pipeline include ATX-MS-1467 for multiple sclerosis, as well as candidates for Factor VIII intolerance and Graves’ disease. The company's proprietary platform technology supports its ongoing development efforts, with its first product candidate already licensed to a major pharmaceutical firm. Through its work, Apitope aims to enhance the quality of life for patients suffering from these challenging diseases.
Trinean is a Belgium based technology provider, bringing micro-volume molecular spectroscopy to the next level by combining best in class analytical software with a highly standardized read-out platform. Founded in 2006 as a spin-out of the Ghent University, Belgium and Imec Leuven, Belgium, the company commercializes UV/VIS spectrometers for biomolecule quantification. The DropSense™16 and DropSense™96, analyzing up to 16 and 96 samples resp., use microfluidic chips for standardized sample analysis (DropPlates™ and Slides). The Trinean platform is complemented with a software toolbox for improved data interpretation and lab-automation.
Genomic Vision is a biotechnology company based in Bagneux, France, specializing in molecular diagnostics and the development of single DNA detection tools for research and in vitro diagnostics. The company utilizes its proprietary technology, known as Molecular Combing, to create innovative products for DNA analysis, genetic testing, and biomarker discovery. Its offerings include the FiberVision platform, which enhances DNA analysis workflows, and various products such as FiberComb, FiberStudio software, and FiberPrep DNA extraction kits. Genomic Vision also provides specialized probes for diagnosing facioscapulohumeral dystrophy and hereditary cancers, as well as combing services that help validate gene editing events and detect genetic anomalies. The company collaborates with several institutions, including Quest Diagnostics and the Institut Pasteur, to further its research and development efforts. Founded in 2004, Genomic Vision is committed to advancing genetic testing technologies in cancer, rare inherited disorders, and pharmacogenomics.